Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Olubunmi Afonja"'
Autor:
Rabi Hanna, Haydar Frangoul, Christopher Mckinney, Luis Pineiro, Markus Mapara, Kai-Hsin Chang, Michael Jaskolka, Keunpyo Kim, Maha Rizk, Olubunmi Afonja, Adebayo Lawal, Mark Walters
Publikováno v:
HemaSphere, Vol 7, p e05170e0 (2023)
Externí odkaz:
https://doaj.org/article/eb39d9d9fabf4d00bd0d947210306f26
Autor:
Rolf Ljung, Anthony K. C. Chan, Heidi Glosli, Olubunmi Afonja, Bastian Becker, Despina Tseneklidou-Stoeter, Maria Elisa Mancuso, Sonata Saulyte-Trakymiene, Gili Kenet
Publikováno v:
Thrombosis and Haemostasis. 123:027-039
Introduction BAY 81–8973, a full-length recombinant factor VIII for hemophilia A treatment, has been extensively evaluated in previously treated patients in the LEOPOLD (Long-Term Efficacy Open-Label Program in Severe Hemophilia A Disease) clinical
Autor:
Maureen Carlyle, Katharine Batt, Ryan Farej, Olubunmi Afonja, Carolyn Martin, John White, Ronald E. Aubert, Robert F. Sidonio
Publikováno v:
Haemophilia. 26:520-528
Aim Haemophilia A (HA) is a male-predominant disorder, yet women and girls can have factor VIII (FVIII) deficiency with bleeding events requiring treatment. This study aimed to identify and characterize female patients with HA. Methods Administrative
Autor:
Olubunmi Afonja, Paul Petraro, Lisa A. Michaels, Robert W. Kozak, Craig M. Kessler, Prasad Mathew, Georg Lemm
Publikováno v:
Expert Review of Hematology. 9:1151-1164
Management and care of individuals with hemophilia A advanced immensely with the introduction of recombinant factor VIII (rFVIII) replacement products. This review provides a historical overview of rFVIII development with a focus on Bayer's rFVIII (w
Autor:
Olubunmi Afonja, Chunmei Liu, Lining Zhang, Xingguo Song, Youhai H. Chen, Yukun Wang, Xia Zhang, Yongyu Shi, Chunhong Ma, Xiaoyan Wang
Publikováno v:
Cancer Science. 101:2163-2170
Chemoresistance is a major cause of treatment failure in ovarian cancer. Therefore, it is necessary to explore alternative therapeutic methods to overcome drug resistance for ovarian cancer treatment. We previously reported that programmed cell death
Autor:
Jie Chen, Maike Zimmermann, Tetsuya S. Tanaka, Olga Genbacev, Joanna Chen, Lu Wang, Pei Su, Jiayu Liao, Susan J. Fisher, Mary C. Horne, Olubunmi Afonja, Fei Wang, Jiaxi Zhou, Enkui Duan
Publikováno v:
Proceedings of the National Academy of Sciences. 106:7840-7845
Despite the recent identification of the transcriptional regulatory circuitry involving SOX2, NANOG, and OCT-4, the intracellular signaling networks that control pluripotency of human embryonic stem cells (hESCs) remain largely undefined. Here, we de
Autor:
Junko H. Ohyashiki, Alec Goldenberg, Kenichi Takeshita, Shuji Nakamura, Takashi Shimamoto, John Smith, Olubunmi Afonja, Kazuma Ohyashiki, Keisuke Toyama, Edward L. Amorosi, Debbie M. Cheng
Publikováno v:
Leukemia Research. 24:849-855
Co-activation of Meisl with Hoxa7 or Hoxa9 homeobox genes by retroviral gene insertion has recently been reported to be leukemogenic in murine myeloid leukemia. In this study we determined their expression in human leukemia. Most human myeloid leukem
Publikováno v:
Oncogene. 23(49)
The growth of human breast tumor cells is regulated through signaling involving cell surface growth factor receptors and nuclear receptors of the steroid/thyroid/retinoid receptor gene family. Retinoic acid receptors (RARs), members of the steroid/th
Autor:
Sharmistha Das, Herbert H. Samuels, Dominique Juste, Olubunmi Afonja, Elizabeth Helmer, Xinyu Zhao, Bruce M. Raaka, Ambrose J. Huang
Publikováno v:
Oncogene. 21(51)
Retinoic acid receptors (RARs) are ligand-dependent transcription factors which are members of the steroid/thyroid hormone receptor gene family. RAR-agonists inhibit the proliferation of many human breast cancer cell lines, particularly those whose g
Autor:
Martin J. Blaser, Robert G. Schacht, Michael Traister, Abigail Freedman, Jane Guttenberg, Guillermo I. Perez-Perez, William Borkowsky, Mary Wu Chang, Herb Lazarus, Olubunmi Afonja, Farzad Mostashari
Publikováno v:
JAMA. 287(7)
A 7-month-old infant with cutaneous anthrax developed severe systemic ill- ness despite early treatment with antibiotics. The infant displayed severe microangiopathic hemolytic anemia with renal involvement, coagulopathy, and hyponatremia. These find